Overview
Congenital secretory diarrhea (CSD), particularly due to Diacylglycerol Acyltransferase 1 (DGAT1) deficiency, is a rare genetic disorder characterized by impaired triglyceride synthesis. This impairment leads to chronic diarrhea, vomiting, growth retardation, and metabolic abnormalities such as hypoalbuminemia and hyperlipidemia. The condition typically manifests within the first few days to weeks after birth, necessitating prompt diagnosis and tailored nutritional management to mitigate severe complications. Understanding the pathophysiology, epidemiology, clinical presentation, diagnosis, and management strategies is crucial for optimizing outcomes in affected infants.
Pathophysiology
Diacylglycerol Acyltransferase 1 (DGAT1) deficiency represents a critical form of congenital diarrheal disease, fundamentally disrupting lipid metabolism. This genetic defect impairs the final step of triglyceride synthesis, leading to a significant reduction in fat absorption and subsequent malabsorption of fat-soluble vitamins. Consequently, affected infants experience chronic diarrhea, often severe and persistent, which can be exacerbated by the concurrent development of protein-losing enteropathy due to the compromised intestinal barrier function [PMID:39548446]. The metabolic derangements extend beyond diarrhea, manifesting as hypoalbuminemia from protein loss and hyperlipidemia due to elevated levels of free fatty acids in the circulation. These physiological imbalances underscore the multifaceted nature of the disease and highlight the importance of comprehensive nutritional support to address both macronutrient and micronutrient deficiencies [PMID:39548446].
Epidemiology
The incidence of DGAT1 deficiency, often categorized under Congenital Oligosaccharide Disorder (CODE), remains exceedingly rare, with limited population-based studies available. However, a notable cohort study spanning from 2006 to 2020 identified 15 children diagnosed with CODE, with a median follow-up period of 2.9 years, emphasizing the chronic nature of the condition and the necessity for long-term management strategies [PMID:38828718]. This small but significant cohort suggests that while the condition is rare, it imposes substantial clinical and logistical challenges requiring specialized care and multidisciplinary approaches. The rarity of the condition also underscores the importance of genetic counseling for families and the need for heightened clinical suspicion in infants presenting with characteristic symptoms early in life.
Clinical Presentation
Infants with DGAT1 deficiency typically present with a constellation of symptoms shortly after birth, often within the first 14 days. Chronic diarrhea, reported in approximately 80% of cases, is the most prominent feature, often accompanied by vomiting in a similar proportion of patients [PMID:39548446]. Abdominal distension, though less frequent, can also be observed in about 20% of cases, reflecting the mechanical effects of malabsorption and fluid accumulation in the gastrointestinal tract. Electrolyte disturbances are universal in these infants, highlighting the risk of dehydration and metabolic imbalances that require vigilant monitoring and correction [PMID:39548446]. Early recognition of these symptoms is crucial, as homozygous DGAT1 deficiency can rapidly progress to severe protein-losing enteropathy, necessitating immediate intervention to prevent further complications such as malnutrition and growth failure [PMID:38934410].
Prenatal findings can also provide early clues to the diagnosis. Ultrasound examinations may reveal generalized bowel dilatation and polyhydramnios, initially suggestive of intestinal obstruction but later indicative of secretory diarrhea [PMID:20069658]. Prenatal MRI can further refine the diagnosis by demonstrating generalized bowel dilatation with intraluminal fluid accumulation and the absence of meconium signal, aiding in timely postnatal management and reducing the risk of severe fluid and electrolyte imbalances at birth [PMID:20069658].
Diagnosis
Diagnosing DGAT1 deficiency relies heavily on genetic testing due to the specificity of the underlying genetic defect. Whole Exome Sequencing (WES) has emerged as a powerful tool, successfully identifying double heterozygous mutations in the DGAT1 gene in all cases studied, thereby confirming the diagnosis [PMID:39548446]. Early genetic diagnosis is pivotal, as it allows for prompt initiation of appropriate nutritional interventions, which can significantly impact clinical outcomes. Prenatal diagnosis through advanced imaging techniques, such as MRI, has also proven valuable. Prenatal MRI findings, including generalized bowel dilatation and the absence of meconium signal, can predict the condition prenatally, enabling clinicians to prepare for immediate postnatal management strategies [PMID:20069658]. This integrated approach combining genetic and imaging modalities ensures a comprehensive diagnostic pathway tailored to the unique needs of these infants.
Management
The cornerstone of managing DGAT1 deficiency involves meticulous nutritional support tailored to the specific metabolic derangements observed. Treatment with low-fat amino acid formulas has demonstrated rapid symptom improvement and catch-up growth in affected infants, underscoring the importance of minimizing fat intake while ensuring adequate protein and caloric provision [PMID:39548446]. More recently, a nutritional protocol involving ultralow fat formulas combined with intermittent peripheral intravenous lipid infusions has shown promising results. This approach not only resolved protein-losing enteropathy but also normalized essential fatty acid status in infants, highlighting the efficacy of targeted nutritional strategies in mitigating clinical symptoms [PMID:38934410]. Early genetic diagnosis facilitating timely implementation of such protocols significantly reduces the reliance on parenteral nutrition (PN), thereby minimizing complications associated with long-term PN use.
Despite the benefits of these nutritional interventions, some infants may still require substantial PN support, particularly in the acute phase. Studies indicate that CODE patients often have higher median PN fluid (83 vs. 45 mL/kg/day) and calorie (54 vs. 30.5 kcal/kg/day) requirements compared to matched Short Bowel Syndrome (SBS) controls, reflecting the severity and complexity of their nutritional needs [PMID:38828718]. However, these patients exhibit mitigated complications related to intestinal failure (IF) compared to SBS controls, suggesting that tailored nutritional management can mitigate some of the more severe outcomes associated with CSD [PMID:38828718].
Complications
Despite advancements in nutritional management, infants with DGAT1 deficiency remain at risk for several complications. While CODE patients require higher levels of parenteral nutrition compared to matched SBS controls, their rates of growth parameters, intestinal failure-associated liver disease (IFALD), central venous catheter complications, and nephrocalcinosis are comparable to those seen in SBS patients [PMID:38828718]. This similarity suggests that while nutritional strategies can mitigate some risks, the underlying condition still poses significant challenges that require vigilant monitoring and multidisciplinary care. The risk of IFALD, in particular, necessitates careful surveillance of liver function and timely interventions to prevent long-term sequelae.
Prognosis & Follow-up
The prognosis for infants with DGAT1 deficiency varies but is generally influenced by the timeliness and efficacy of interventions. Early treatment with low-fat amino acid diets and advanced nutritional protocols has led to rapid clinical improvement and positive growth trends, underscoring the critical importance of early diagnosis and intervention [PMID:39548446]. Longitudinal studies indicate that while these interventions promote normal growth and development in treated infants, the overall prognosis remains guarded. For instance, CODE patients exhibit significantly lower 10-year survival rates (60%) and enteral autonomy (30%) compared to non-matched SBS populations (89% and 87%, respectively), highlighting persistent challenges despite improved management strategies [PMID:38828718]. Regular follow-up is essential to monitor growth parameters, nutritional status, and potential complications, ensuring that adjustments to the management plan can be made promptly to optimize outcomes.
Key Recommendations
References
1 Zheng Y, Li Y, Zheng C, Yang L, Zhang C, Huang Y et al.. A low-fat amino acid diet reverses intestinal failure and shows good growth trends in five infants with diacylglycerol transferase 1 (DGAT1) deficiency: a prospective cohort study. Lipids in health and disease 2024. link 2 Millman P, Rimon RM, Toff C, Engvall M, Shaoul R, Wilschanski M et al.. A novel nutritional approach to infants and children with congenital diarrhea due to homozygous DGAT1 mutations. Journal of pediatric gastroenterology and nutrition 2024. link 3 Spector Cohen I, Belza C, Courtney-Martin G, Srbely V, Wales PW, Muise A et al.. Improved long-term outcome of children with congenital diarrhea followed by an intestinal rehabilitation program. Journal of pediatric gastroenterology and nutrition 2024. link 4 Colombani M, Ferry M, Toga C, Lacroze V, Rubesova E, Barth RA et al.. Magnetic resonance imaging in the prenatal diagnosis of congenital diarrhea. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2010. link